|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1010 - 0.1010|
|52 Week Range||0.0700 - 0.2200|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||0.37|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its board of directors (the “Board”), including Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D., and Eric Richman, M.B.A, to become effective upon the closing of the Company’s merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The four designees, together with Dietrich A. Stephan, Ph.D., chairman and chief executive officer of the company, will comprise the entire board of directors for the combined company.
NovelStem International Corp. (OTC Pink: NSTM) is focused on the substantial commercial potential of stem-cell-based diagnostic technology to aid the selection of cancer chemotherapy agents, which technology is being developed by its 20%-owned affiliate, NewStem Ltd. NovelStem expects to provide a shareholder update on NewStem’s progress within the next month. NovelStem announced today that its 50% owned Netco Partners unit has executed an agreement with Hanover Square Press, an imprint of HarperCollins, to relaunch the “Net Force” book series. Hanover Square Press acquired publishing rights to four novels and four e-novellas in the series and anticipates the first launch, Net Force: Dark Web, to take place in October with one novel and one e-novella expected per year.